Those with PE were more than three times more likely to die in the 30 days after treatment and 1.4 times more likely to die over a three year period.
Among the 549 patients with PE, 31 (5.7%) had a recurrent clot in the long, 75 (13.7%) had a recurrence of either type of VTE and 14.9% had a major bleeding episode.
In the VTE only group, 5.6% developed pulmonary embolism, 19% had recurrent VTE and 12.8% had a major bleeding episode.
Authors wrote: ‘Efforts are needed to identify patients most at risk for venous thrombosis-associated complications and to develop better anticoagulation strategies conducive to long-term use in the community setting.’
Archives of Internal Medicine (2008) 168: 425-430